Jonathan Gillis sold $2.1M of MPLT
CAAO and PAO at MapLight Therapeutics, Inc.. 69,835 shares at an average of $29.89, traded Apr 27, 2026, filed Apr 29, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.1M at market
- +10Share of holdings soldSold 28% of holdings
- +15Cluster8 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.2%, 3m -50.4%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001709954-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -7,914 | $28.94 | $229k | 243,140 | Apr 29, 2026 |
| Apr 27, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -29,623 | $29.60 | $877k | 213,517 | Apr 29, 2026 |
| Apr 27, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -14,363 | $30.46 | $437k | 199,154 | Apr 29, 2026 |
| Apr 28, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -17,235 | $30.33 | $523k | 181,919 | Apr 29, 2026 |
| Apr 28, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -700 | $30.83 | $22k | 181,219 | Apr 29, 2026 |
Related signals
Other insiders at MapLight Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $193k 16,509 shares | -11% | |
| 51Moderate | MPLTbuy MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $50M 4,400,000 shares | +21% | |
| 9Weak | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $277k 22,082 shares | -10% | |
| 51Moderate | MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $15M 1,209,225 shares | +6% | |
| 50Moderate | MapLight Therapeutics, Inc. | Troy Cox director | $149k 15,620 shares | - | |
| 47Moderate | MapLight Therapeutics, Inc. | Jonathan Gillis CAO and Interim CFO | $1.4M 36,979 shares | -20% | |
| 40Moderate | MapLight Therapeutics, Inc. | Anatol Kreitzer Chief Discovery Officer | $1.3M 36,284 shares | -17% | |
| 40Moderate | MapLight Therapeutics, Inc. | Erin Pennock Foff Chief Medical Officer | $1.7M 47,158 shares | -14% | |
| 55Moderate | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $608k 16,508 shares | -10% | |
| 70Notable | MapLight Therapeutics, Inc. | Christopher A. Kroeger Chief Executive Officer | $5.4M 147,639 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.